Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication

Clinical Cardiology

Volumn 25, Issue 3, 2002, Pages 91-94

  Smith, James A M ^a  

^a USA   (United States)

Author keywords

Cilostazol; Clinical trial endpoints; Intermittent claudication; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; MEVINOLIN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; TRIACYLGLYCEROL; WARFARIN;

ANTICOAGULATION; ARTERY DISEASE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HEADACHE; HEART PALPITATION; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LEG PAIN; NONHUMAN; QUALITY OF LIFE; REVIEW; TACHYCARDIA; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; WALKING;

EID: 0036186668     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960250303     Document Type: Review

References (35)

1. Update on some epidemiologic features of intermittent claudication: The Framingham study
2. Epidemiology and prognostic significance of peripheral arterial disease
3. Management of peripheral arterial disease (PAD)
4. Exercise training improves functional status in patients with peripheral arterial disease
5. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease
6. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points
7. The evaluation of exercise performance in patients with peripheral vascular disease
8. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease
9. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: Summary of results from the medical outcomes study
10. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease
11. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
12. Antithrombotic therapy in peripheral arterial occlusive disease
13. New Drugs of 1999
14. Research and development of cilostazol: An antiplatelet agent
15. Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia
16. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease
17. The localization of a new antithrombotic agent, cilostazol, in CHO-K1 cells as demonstrated by autoradiography
18. Effect of cilostazol on platelet aggregation and experimental thrombosis
19. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities
20. Characteristics of heparin-induced platelet aggregates in chronic hemodialysis with long-term heparin use
21. The potential of cilostazol in interventional cardiology
22. Cilostazol, a selective type III phosphodiesterase inhibitor. Decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats
23. Cilostazol. A phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat. A model of spontaneous NIDDM
24. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
25. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
26. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
27. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
28. Cilostazol for use in patients with intermittent claudication
29. Two doses of cilostazol versus placebo in the treatment of claudication: Results of a randomized, multicenter trial (abstr)
30. The effect of withdrawal of drugs treating intermittent claudication
31. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites
32. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol
33. Interaction potential and tolerability of the coadministration of cilostazol and aspirin
34. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin
35. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers